| Ident. | Authors (with country if any) | Title |
|---|
| 000076 (2013) |
M. Lagière [France] ; S. Navailles [France] ; L. Mignon [États-Unis] ; A. Roumegous [France] ; M.-F. Chesselet [États-Unis] ; P. De Deurwaerdère [France] | The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates |
| 000109 (2013) |
Omar Ouachikh [France] ; Wisam Dieb [France] ; Franck Durif [France] ; Aziz Hafidi [France] | Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area |
| 000267 (2011) |
Sophie Bayard [France] ; Valérie Cochen De Cock [France] ; Yves Dauvillers [France] | Le syndrome de dysrégulation dopaminergique dans la maladie de Parkinson et le syndrome des jambes sans repos |
| 000272 (2011) |
L. Bindler [France] ; M. Anheim [France] ; C. Tranchant [France] ; P. Vidailhet [France] | La créativité du patient parkinsonien |
| 000353 (2011) |
Ngoc-Duc Doan [Canada] ; Steve Bourgault [Canada] ; Agnieszka Dejda [Canada] ; Myriam Letourneau [Canada] ; Michel Detheux [Belgique] ; David Vaudry [Canada, France] ; Hubert Vaudry [Canada, France] ; David Chatenet [Canada] ; Alain Fournier [Canada] | Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects |
| 000502 (2010) |
Santiago Perez-Lloret [France, Argentine] ; Olivier Rascol [France] | Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson's Disease |
| 000507 (2010) |
A. Faure [France] ; P. Leblanc-Veyrac [France] ; N. El Massioui [France] | DOPAMINE AGONISTS INCREASE PERSEVERATIVE INSTRUMENTAL RESPONSES BUT DO NOT RESTORE HABIT FORMATION IN A RAT MODEL OF PARKINSONISM |
| 000592 (2009) |
S. Bourgault [Canada, France] ; D. Vaudry [France] ; A. Dejda [Canada, France] ; N. D. Doan [Canada, France] ; H. Vaudry [France] ; A. Fournier [Canada, France] | Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure-Activity Relationships of a Neuroprotective Peptide |
| 000680 (2008) |
Pierre Cesaro [France] | Neuroprotection et maladie de Parkinson |
| 000695 (2008) |
J.-M. Gerard [France] | Initiation du traitement de la maladie de Parkinson et son adaptation en fonction de l'évolution |
| 000737 (2008) |
Dieter Scheller [Allemagne] ; Christine Stichel-Gunkel [Allemagne] ; Hermann Lübbert [Allemagne] ; Gregory Porras [France] ; Paula Ravenscroft [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Erwan Bezard [France, Royaume-Uni] | Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease |
| 000777 (2008) |
A. Marighetto [France] ; S. Valerio [France] ; J. N. Philippin [France] ; V. Bertaina-Anglade [France] ; C. Drieu La Rochelle [France] ; R. Jaffard [France] ; P. Morain [France] | Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents |
| 000845 (2007) |
Pauline Sibille [France] ; Sébastien Lopez [France] ; Isabelle Brabet [France] ; Omella Valenti [États-Unis] ; Nadia Oueslati [France] ; Florence Gaven [France] ; Cyril Goudet [France] ; Hugues-Olivier Bertrand [France] ; Jacques Neyton [France] ; Michael J. Marino [États-Unis] ; Marianne Amalric [France] ; Jean-Philippe Pin [France] ; Francine C. Acher [France] | Synthesis and biological evaluation of 1 -amino -2 -phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists |
| 000875 (2007) |
Heike Wulff [États-Unis] ; Aaron Kolski-Andreaco [États-Unis] ; Ananthakrishnan Sankaranarayanan [États-Unis] ; Jean-Marc Sabatier [France] ; Vikram Shakkottai [États-Unis] | Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications |
| 000937 (2006) |
Jean-Louis Montastruc [France] ; Agnès Sommet [France] ; Pascale Olivier [France] ; Haieh Bagheri [France] ; Mireille Gony [France] ; Maryse Lapeyre-Mestre [France] ; Christine Brefel-Courbon [France] ; Joachim Ferreira [Portugal] ; Laurent Schmitt [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] | Médicaments, maladie de Parkinson et syndromes parkinsoniens : actualités de pharmacovigilance |
| 000984 (2006) |
Dominique Drapier [France] ; Sophie Drapier [France] ; Paul Sauleau [France] ; Pascal Derkinderen [France] ; Philippe Damier [France] ; Herve Allain [France] ; Marc Verin [France] ; Bruno Millet [France] | Pathological gambling secondary to dopaminergic therapy in Parkinson's disease |
| 000C85 (2003) |
F. Ghawche [France] ; F. Durif [France] | Traitement dopaminergique et syndromes parkinsoniens |
| 000D22 (2003) |
J.-L. Montastruc [France] ; L. Schmitt [France] ; H. Bagheri [France] | Comportement pathologique de jeu au cours d'une maladie de Parkinson traitée par lévodopa et bromocriptine |
| 000D41 (2003) |
R. Bordet [France] ; D. Devos [France] ; S. Brique [France] ; Y. Touitou [France] ; J. D. Guieu [France] ; C. Libersa [France] ; A. Destee [France] | Study of circadian melatonin secretion pattern at different stages of Parkinson's disease |
| 000D42 (2003) |
Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni] | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study |
| 000D70 (2003) |
Olivier Rascol [France] ; Pierre Payoux [France, Portugal] ; Fabienne Ory [France] ; Joaquim J. Ferreira [France] ; Christine Brefel-Courbon [France] ; Jean-Louis Montastruc [France] | Limitations of current Parkinson's disease therapy. Discussion |
